Table 2. Antineoplastic drugs that prolong the QT interval.
| Drugs | Effect of QT | TdP | References |
|---|---|---|---|
| Classic drugs | |||
| Arsenic Trioxide | 37% with 30–60 ms↑, 35% with > than 60 ms↑ | + | [23, 26, 27] |
| Anthracycline | 9.56 ms↑in doxorubicin therapy | + | [32] |
| Tamoxifen | Dose related | possible | [34] |
| Platinum compounds | 6.25% in cisplatin treatment, no data for oxaliplatin treatment |
+ (oxaliplatin) |
[36, 38, 39] |
| 5-fluorouracil (5-FU) | Significant increases in QTmax and QTd were observed as early as 24 h after 5-FU treatment | − | [40] |
| Cesium chloride | QT prolongation usually occurs with total cesium intakes of 6 g/day | + | [41–44] |
| Molecularly-targeted drugs | |||
| Trastuzumab | Prolongs QT interval with long-term treatment (12 weeks) | − | [46] |
| HDAC inhibitors | 36% with vorinostat treatment |
+ (vorinostat and depsipeptide) |
[49–52] |
| Rituximab(possible) | 1 case report | possible | [67] |
| TKIs | Varieties of TKIs could lead to QT interval prolongation. | − | [54-61, 84-90] |
| CA4P | 23.3% QTc prolongation | − | [71] |
| BRAF inhibitors | Vemurafenib and Dabrafenib | − | [74, 91] |
| Eribulin | a minor prolongation of QTc | − | [92] |
| Bortezonib | 2 of 11 patients showed QT interval prolongation | + | [93] |